RT Journal Article
SR Electronic
T1 The feasibility of convalescent plasma therapy in severe COVID- 19 patients: a pilot study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.16.20036145
DO 10.1101/2020.03.16.20036145
A1 Kai Duan
A1 Bende Liu
A1 Cesheng Li
A1 Huajun Zhang
A1 Ting Yu
A1 Jieming Qu
A1 Min Zhou
A1 Li Chen
A1 Shengli Meng
A1 Yong Hu
A1 Cheng Peng
A1 Mingchao Yuan
A1 Jinyan Huang
A1 Zejun Wang
A1 Jianhong Yu
A1 Xiaoxiao Gao
A1 Dan Wang
A1 Xiaoqi Yu
A1 Li Li
A1 Jiayou Zhang
A1 Xiao Wu
A1 Bei Li
A1 Yanping Xu
A1 Wei Chen
A1 Yan Peng
A1 Yeqin Hu
A1 Lianzhen Lin
A1 Xuefei Liu
A1 Shihe Huang
A1 Zhijun Zhou
A1 Lianghao Zhang
A1 Yue Wang
A1 Zhi Zhang
A1 Kun Deng
A1 Zhiwu Xia
A1 Qin Gong
A1 Wei Zhang
A1 Xiaobei Zheng
A1 Ying Liu
A1 Huichuan Yang
A1 Dongbo Zhou
A1 Ding Yu
A1 Jifeng Hou
A1 Zhengli Shi
A1 Chen Saijuan
A1 Zhu Chen
A1 Xinxin Zhang
A1 Xiaoming Yang
YR 2020
UL http://medrxiv.org/content/early/2020/03/23/2020.03.16.20036145.abstract
AB Currently, there are no approved specific antiviral agents for 2019 novel coronavirus disease (COVID-19). In this study, ten severe patients confirmed by real-time viral RNA test were enrolled prospectively. One dose of 200 mL convalescent plasma (CP) derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to maximal supportive care and antiviral agents. The primary endpoint was the safety of CP transfusion. The second endpoints were the improvement of clinical symptoms and laboratory parameters within 3 days after CP transfusion. The median time from onset of illness to CP transfusion was 16.5 days. After CP transfusion, the level of neutralizing antibody increased rapidly up to 1:640 in five cases, while that of the other four cases maintained at a high level (1:640). The clinical symptoms were significantly improved along with increase of oxyhemoglobin saturation within 3 days. Several parameters tended to improve as compared to pre-transfusion, including increased lymphocyte counts (0.65×109/L vs. 0.76×109/L) and decreased C-reactive protein (55.98 mg/L vs. 18.13 mg/L). Radiological examinations showed varying degrees of absorption of lung lesionswithin 7 days. The viral load was undetectable after transfusion in seven patients who had previous viremia. No severe adverse effects were observed. This study showed CP therapy was welltolerated and could potentially improve the clinical outcomes through neutralizing viremia in severe COVID-19 cases. The optimal dose and time point, as well as the clinical benefit of CP therapy, needs further investigation in larger well-controlled trials.Significance Statement COVID-19 is currently a big threat to global health. However, no specific antiviral agents are available for its treatment. In this work, we explored the feasibility of convalescent plasma (CP) transfusion to rescue severe patients. The results from 10 severe adult cases showed that one dose (200 mL) of CP was welltolerated and could significantly increase or maintain the neutralizing antibodies at a high level, leading to disappearance of viremia in 7 days. Meanwhile, clinical symptoms and paraclinical criteria rapidly improved within 3 days. Radiological examination showed varying degrees of absorption of lung lesions within 7 days. These results indicate that CP can serve as a promising rescue option for severe COVID-19 while the randomized trial is warranted.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialChiCTR2000030048Funding StatementThis study was funded by Key projects of the Ministry of Science and Technology China “Preparation of specific plasma and specific globulin from patients with a recovery period of COVID-19 infection” (project number: 2020YFC0841800).This work was also supported by Shanghai Guangci Translational Medicine Development Foundation.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data associated with the manuscript were available on request